Vaughan David Investments LLC IL Cuts Position in Johnson & Johnson $JNJ

Posted by George Bondi on Jun 12th, 2026

Vaughan David Investments LLC IL decreased its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 314,276 shares of the company’s stock after selling 2,517 shares during the quarter. Johnson & Johnson comprises approximately 1.4% of Vaughan David Investments LLC IL’s portfolio, making the stock its 15th biggest holding. Vaughan David Investments LLC IL’s holdings in Johnson & Johnson were worth $65,039,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Greenberg Financial Group purchased a new position in Johnson & Johnson in the fourth quarter worth $954,000. Varma Mutual Pension Insurance Co increased its position in shares of Johnson & Johnson by 8.9% in the third quarter. Varma Mutual Pension Insurance Co now owns 378,256 shares of the company’s stock valued at $70,136,000 after buying an additional 30,900 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Johnson & Johnson by 4.3% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,030,835 shares of the company’s stock valued at $932,835,000 after buying an additional 208,765 shares in the last quarter. JT Stratford LLC increased its position in shares of Johnson & Johnson by 7.6% in the third quarter. JT Stratford LLC now owns 59,577 shares of the company’s stock valued at $11,047,000 after buying an additional 4,216 shares in the last quarter. Finally, World Investment Advisors increased its position in shares of Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after buying an additional 26,450 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on JNJ. Rothschild & Co Redburn raised their price target on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, April 24th. The Goldman Sachs Group raised their price target on Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, April 15th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a research report on Wednesday, May 13th. Twenty analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $253.04.

Read Our Latest Research Report on Johnson & Johnson

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson reported encouraging late-stage results for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia, showing statistically significant durable hemoglobin response and rapid onset of effect in a disease with no FDA-approved treatment options. That supports the company’s immunology pipeline and possible future revenue growth. Article Title
Positive Sentiment: The company expanded U.S. availability of TECNIS PureSee, an advanced cataract lens option, adding another incremental growth driver in medtech and reinforcing its leadership in eye care. Article Title
Positive Sentiment: J&J announced plans to acquire Firefly Bio for about $1 billion, a move aimed at strengthening its cancer-treatment pipeline and signaling continued deal-making to support long-term growth. Article Title
Positive Sentiment: Multiple analyst/commentary pieces remained constructive on JNJ’s valuation, with investors highlighting its “discount” relative to quality, strong drug profits, and AAA balance-sheet profile. Article Title
Neutral Sentiment: Several articles reiterated that J&J remains a favored defensive dividend stock, which supports investor interest but does not change fundamentals on its own. Article Title
Negative Sentiment: A Los Angeles jury awarded $32 million in a talc/asbestos case, renewing legal risk concerns that have long weighed on Johnson & Johnson’s shares and could keep a lid on valuation. Article Title
Negative Sentiment: Coverage of the latest talc verdict underscores that litigation remains an important risk factor investors are still watching closely. Article Title

Johnson & Johnson Trading Up 0.0%

Johnson & Johnson stock opened at $238.59 on Friday. The stock has a market cap of $574.33 billion, a PE ratio of 27.58, a P/E/G ratio of 2.34 and a beta of 0.26. The stock has a 50-day moving average price of $231.58 and a 200 day moving average price of $227.11. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a dividend of $1.34 per share. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is 61.97%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.